The virus could slip past immunity people had already built
En los primeros días de septiembre de 2021, Perú se encontró rastreando una nueva variable del destino pandémico: la variante Mu del COVID-19, ya presente en trece regiones del país desde su primera aparición en Moquegua en mayo. Como tantas veces en la historia de las enfermedades infecciosas, la amenaza no llegó de golpe sino en silencio, acumulándose hasta hacerse visible. Las autoridades sanitarias advierten sobre su posible capacidad de evadir la inmunidad adquirida, aunque los datos iniciales ofrecen un matiz esperanzador: los vacunados infectados no desarrollaron enfermedad grave.
- El Instituto Nacional de Salud confirmó 67 casos de la variante Mu dispersos en 13 regiones, desde Moquegua hasta Lima y Callao, revelando una propagación silenciosa que ya atravesaba el país.
- La variante, clasificada por la OMS como de interés y detectada en 39 países, porta mutaciones en la proteína spike que podrían permitirle escapar de las defensas inmunitarias generadas por infección previa o vacunación.
- Diez personas vacunadas contrajeron COVID-19 por esta variante, encendiendo alarmas sobre la efectividad de las vacunas frente a Mu, aunque ninguna desarrolló enfermedad severa.
- El Ministerio de Salud ya anticipa una posible tercera ola en los próximos meses, y la presencia de una variante con potencial resistencia inmunitaria añade una capa de incertidumbre crítica a esa planificación.
- Las autoridades sanitarias insisten en que las vacunas siguen cumpliendo su función más importante: evitar los desenlaces graves, incluso si no garantizan protección total frente a la infección.
A comienzos de septiembre de 2021, el Instituto Nacional de Salud del Perú confirmó 67 casos de la variante Mu del COVID-19 en trece regiones del país. El primer caso había sido detectado en mayo en Moquegua, pero para cuando las autoridades hicieron el anuncio público, la variante ya había llegado a Tacna, Arequipa, Lima, Callao y otras zonas del territorio nacional.
La médica infectóloga Lely Solari explicó en una entrevista radial que la variante Mu, identificada por primera vez en Colombia en enero de 2021, portaba mutaciones en la proteína spike que preocupaban a los epidemiólogos. La Organización Mundial de la Salud la había clasificado como variante de interés y seguía su presencia en 39 países. Lo que distinguía a Mu era la posibilidad de que sus cambios genéticos le permitieran evadir la inmunidad desarrollada tanto por infección previa como por vacunación.
Sin embargo, los datos peruanos ofrecían cierto alivio. De los 67 casos confirmados, diez correspondían a personas ya vacunadas que contrajeron el virus de todas formas. Pero ninguna de ellas desarrolló enfermedad grave. Las vacunas, al parecer, seguían cumpliendo su función esencial: proteger frente a los peores desenlaces, aunque no siempre frente a la infección misma.
El anuncio llegó en un momento de particular tensión. El Ministerio de Salud ya anticipaba una posible tercera ola de contagios en los meses siguientes. La presencia de una variante con potencial resistencia inmunitaria extendiéndose por trece regiones añadía una nueva capa de complejidad a la respuesta sanitaria, obligando a las autoridades a vigilar de cerca cómo se comportaría Mu en la población peruana y si el patrón de enfermedad leve en vacunados se mantendría con el tiempo.
By early September 2021, Peru's National Health Institute had identified sixty-seven confirmed cases of the Mu variant of COVID-19 scattered across thirteen regions of the country. The first patient had surfaced in Moquegua back in May. By the time health officials made the announcement public, the variant had already reached Tacna, Arequipa, Lima, Callao, and numerous other zones across the nation's territory.
Lely Solari, an infectious disease physician at the National Health Institute under Peru's Ministry of Health, delivered the news in an interview with RPP radio. She explained that the Mu variant, first detected internationally in Colombia in January, carried a particular set of mutations that concerned epidemiologists worldwide. The World Health Organization had classified it as a variant of interest and tracked its presence in thirty-nine countries by that point. What made Mu distinctive—and worrying—was the possibility that its genetic changes might allow it to evade immune responses that people had built up either through previous infection or through vaccination.
Solari was careful to explain the mechanism. The variant possessed mutations in the spike protein that suggested it could potentially slip past immunity that individuals had already developed. This meant that people who had been exposed to the virus before, whether through natural infection or through vaccination, could still become infected again. The World Health Organization had flagged this possibility as a form of immune escape—the virus's ability to outmaneuver the body's defenses.
Yet there was a measure of reassurance in the data so far. Among the sixty-seven confirmed cases in Peru, ten of the infected individuals had already been vaccinated. Despite this breakthrough infection, Solari emphasized that none of these ten patients had developed severe disease. They had contracted COVID-19, yes, but their illness remained mild. The vaccines, it seemed, were still doing their job of preventing the worst outcomes, even if they could not always prevent infection altogether.
Scientists in Colombia, where the variant had first emerged, had identified three specific mutations in the spike protein that suggested Mu might transmit more readily than other variants circulating at the time. But researchers remained cautious about drawing firm conclusions. It was not yet clear whether the variant itself was inherently more transmissible or whether its spread in Peru and elsewhere reflected broader epidemiological patterns—the movement of people, the density of populations, the timing of exposure.
The timing of this announcement carried weight. Peru's Ministry of Health was already bracing for what officials believed would be a third wave of coronavirus infections in the months ahead. Cases and deaths remained relatively low at that moment, but the trajectory was uncertain. The presence of a potentially vaccine-resistant variant spreading across thirteen regions added another layer of complexity to pandemic planning. Health authorities would need to monitor how Mu behaved in the Peruvian population, whether it would accelerate transmission, and whether the pattern of mild disease in vaccinated individuals would hold as the variant encountered more people.
Notable Quotes
This variant has mutations that suggest immune escape—people already exposed to the virus through infection or vaccination can still become infected— Lely Solari, infectious disease physician, National Health Institute
None of the ten vaccinated patients who contracted the variant presented severe infection— Lely Solari, National Health Institute
The Hearth Conversation Another angle on the story
Why does this variant matter if vaccinated people aren't getting severely ill?
Because we don't know yet if that pattern will hold. Ten cases is a small sample. If Mu spreads widely and infects thousands of vaccinated people, even a small percentage developing severe illness could overwhelm hospitals.
The source mentions mutations in the spike protein. What does that actually mean for someone getting infected?
The spike protein is how the virus enters your cells. Mutations there can make it harder for your immune system to recognize and stop the virus—like a burglar changing his appearance so the security guard doesn't recognize him.
Colombia detected this first. Why is Peru reporting cases so quickly after?
Peru has a functioning surveillance system through the National Health Institute. But it also suggests the variant is already circulating widely. May to September is four months—plenty of time for it to spread across borders and regions.
The article mentions a potential third wave. Is Mu causing that, or is something else?
That's the uncertainty. Peru's health ministry was already predicting a third wave based on seasonal patterns and behavior. Mu's arrival just means that wave, if it comes, might be harder to control.
What happens next? Do they change the vaccination strategy?
The source doesn't say. But typically, health authorities would increase surveillance, possibly sequence more cases to track Mu's spread, and watch whether severe illness rates change. That's the real test.